Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Venous Thrombosis 1Stomach Neoplasms 1Prostatic Neoplasms 1Postoperative Complications 1Lymphedema 1Intestinal Neoplasms 1Gastrointestinal Neoplasms 1

Interventions

Dalteparin 11apixaban 9Enoxaparin 7edoxaban 5Tinzaparin 5Rivaroxaban 4Heparin, Low-Molecular-Weight 4Dabigatran 3bemiparin 2abelacimab 2Warfarin 2Nadroparin 2MAA868 2Fondaparinux 2reviparin 1myotubularin 1isoquercitrin 1certoparin 1atezolizumab 1acarboxyprothrombin 1Ultrasonography, Doppler, Duplex 1Rosuvastatin Calcium 1Phenprocoumon 1Models, Biological 1Medication Therapy Management 1Intermittent Pneumatic Compression Devices 1Imaging, Three-Dimensional 1Hospitals 1Heparin 1Fluorodeoxyglucose F18 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Venous Thrombosis × Intermittent Pneumatic Compression Devices × Clear all
NCT00539942 2017-03-27

Study of Arixtra (Fondaparinux Sodium) to Prevent Blood Clots in Women Undergoing Abdominopelvic Surgery for Likely Gynecologic Malignancy

University of Alabama at Birmingham

Phase 3 Terminated
7 enrolled 9 charts

Postoperative Complications, Venous Thrombosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡